Login to Your Account



MARKET HYPERSENSITIVE?

Blood pressure: Baxter hemo A phase III solid, safety upside a 'factor'

By Randy Osborne
Staff Writer

Thursday, August 21, 2014
Baxter International Inc. unveiled favorable phase III data from the pivotal trial with BAX 855, an extended half-life recombinant factor VIII (rFVIII) antagonist for hemophilia A. 

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription